A wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) has entered into definitive agreements to invest USD 200 million for an approximate 3% equity interest in Micro Life Sciences Pvt. Ltd., the parent company of leading Indian medical technology firm Meril. The investment implies an enterprise valuation of approximately USD 6.6 billion for Meril and remains subject to regulatory approval from the Competition Commission of India. Upon completion, Meril will be backed by both ADIA and existing investor Warburg Pincus.
Founded by the Bilakhia Group, Meril is a globally recognised MedTech enterprise offering advanced clinical technologies across a diverse range of therapeutic areas, including cardiovascular and structural heart interventions, orthopaedics, endo-surgery, in-vitro diagnostics, and surgical robotics.
For the financial year 2024, the company reported consolidated revenue of ₹3,496 crore, representing a notable increase from ₹2,358 crore in the previous year. Despite the growth in top-line performance, net profit declined from ₹483.4 crore to ₹332.8 crore.
Meril currently employs over 13,000 professionals and operates from a 100-acre, fully green-powered, vertically integrated MedTech campus in Vapi, Gujarat. The company maintains a global presence through more than 35 subsidiaries across over 150 countries and supports the training and upskilling of more than 10,000 healthcare professionals annually via 12 international training academies.
Sanjeev Bhatt, Senior Vice President – Strategy at Meril, stated that the investment reinforces institutional confidence in the company’s long-term strategy and global aspirations. He added that the capital infusion will support accelerated growth, the recruitment of top-tier talent, and enhanced investments in research and clinical development, further strengthening Meril’s commitment to delivering innovative healthcare solutions worldwide.
